KROS vs UNH

Keros Therapeutics still possesses significant long-term 10x potential due to its deep pipeline targeting large unmet medical needs via the validated TGF-beta pathway. The Takeda licensing deal for KER-012, now progressing to Phase 3, validates the platform and offers future milestones. However, recent Q1 2026 earnings were abysmal, showing a near 100% year-over-year revenue decline and a swing to...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...